Quick Summary:
The continuous growth of the Pulmonary Arterial Hypertension (PAH) market underscores its dynamic and lucrative nature, especially considering the increasing global prevalence of PAH disease. In the face of this public health challenge, our market research report provides invaluable insights into the key trends, therapeutic advances, and strategic moves transforming this sector.
The report offers an extensive diagnosis of key market aspects, focusing on the leading medications such as endothelin receptor antagonists and PDE-5 inhibitors. Furthermore, the report minutely scrutinizes prominent market players, emerging trends, and impactful technological advancements. For instance, global giants like the Merck Group and United Therapeutics Corporation that leave significant footprints in the pharmaceutical landscape, reveal up-to-the-minute strategies such as monumental acquisitions or break-through drug launches. Arming yourself with this knowledge allows you to navigate the market dynamics effectively and confidently, ensuring you're poised to capitalize on arising opportunities.
Pulmonary arterial hypertension refers to a form of excessive blood pressure that harms the right side of the heart and the arteries in the lungs. The lungs' artery walls become constricted and rigid due to this long-lasting, incurable condition. The pulmonary arterial hypertension drugs relax the muscles in the walls of the blood vessels, increase the blood flow through the lungs, or reverse the effect of the substance in the walls of blood vessels that causes them to narrow.
The main types of pulmonary arterial hypertension drug classes are endothelin receptor antagonists (ERAS), PDE-5 inhibitors, prostacyclin and prostacyclin analogs, and SGC stimulators. Endothelin receptor antagonists (ERAs) are a form of targeted medication that is used to treat pulmonary hypertension in patients (PH). Targeted medicines can help to reduce the course of PH and potentially reverse some of the heart and lung damage. The drugs are administered through oral, intravenous/subcutaneous, and inhalational modes and distributed through retail and online channels.
The global pulmonary arterial hypertension market grew from $7.05 billion in 2022 to $7.63 billion in 2023 at a compound annual growth rate (CAGR) of 8.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The pulmonary arterial hypertension market is expected to grow to $10.47 billion in 2027 at a CAGR of 8.2%.
The pulmonary arterial hypertension market research report is one of a series of new reports that provides pulmonary arterial hypertension market statistics, including pulmonary arterial hypertension industry global market size, regional shares, competitors with a pulmonary arterial hypertension market share, detailed pulmonary arterial hypertension market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonary arterial hypertension industry. This pulmonary arterial hypertension market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Technological advancements are key trends gaining popularity in the pulmonary arterial hypertension market. The companies operating in the pulmonary arterial hypertension drug sector are focusing on developing new medicines to improve and cure these diseases. For instance, in April 2021, United Therapeutics Corporation, a US-based biotechnology company, launched Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease. Tyvaso is an inhalation solution that helps patients enhance their exercise abilities, reduce breathing difficulties, have a low tolerance for exertion, and have a higher mortality rate.
In September 2021, Merck Group, a German-based multinational science and technology company that specialises in healthcare and life sciences solutions, acquired Acceleron Pharma for $11 billion. Through this acquisition, Merck will obtain ownership of Acceleron's portfolio of rare illness therapies, including sotatercept, a Phase III pulmonary arterial hypertension (PAH) medication, and also puts the company at the forefront of rare disease-focused companies. Acceleron Pharma is a US-based company committed to the research, development, and commercialization of therapies for the treatment of critical and uncommon conditions such as pulmonary arterial hypertension.
North America was the largest region in the pulmonary arterial hypertension market in 2022. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the pulmonary arterial hypertension market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The increasing prevalence of pulmonary arterial hypertension (PAH) disease is contributing to the growth of the pulmonary arterial hypertension market. The increasing prevalence of PAH diseases and the related hospitalisation of patients for treatment is expected to boost the demand for relevant drugs during the forecast period. According to a study published by the National Organization for Rare Disorders, Inc., new cases of PAH are estimated to occur in one to two individuals per million each year in the USA, which equates to 500-1000 new cases each year, and Europe is expected to have similar incidence rates.
The pulmonary arterial hypertension market includes revenues earned by entities by idiopathic, heritable, and drug and toxin-induced. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Major players in the pulmonary arterial hypertension market are United Therapeutics Corporation, Bayer AG, Gilead Sciences Inc., Johnson & Johnson, GlaxoSmithKline, Pfizer Inc., Sandoz AG, Lupin Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Acceleron Pharma Inc., Eli Lilly and Company, Actelion Pharmaceuticals US Inc., Natco Pharma Ltd., Zydus Pharmaceutical USA, and Liquidia Technologies Inc.,
This product will be delivered within 1-3 business days.
The main types of pulmonary arterial hypertension drug classes are endothelin receptor antagonists (ERAS), PDE-5 inhibitors, prostacyclin and prostacyclin analogs, and SGC stimulators. Endothelin receptor antagonists (ERAs) are a form of targeted medication that is used to treat pulmonary hypertension in patients (PH). Targeted medicines can help to reduce the course of PH and potentially reverse some of the heart and lung damage. The drugs are administered through oral, intravenous/subcutaneous, and inhalational modes and distributed through retail and online channels.
The global pulmonary arterial hypertension market grew from $7.05 billion in 2022 to $7.63 billion in 2023 at a compound annual growth rate (CAGR) of 8.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The pulmonary arterial hypertension market is expected to grow to $10.47 billion in 2027 at a CAGR of 8.2%.
The pulmonary arterial hypertension market research report is one of a series of new reports that provides pulmonary arterial hypertension market statistics, including pulmonary arterial hypertension industry global market size, regional shares, competitors with a pulmonary arterial hypertension market share, detailed pulmonary arterial hypertension market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonary arterial hypertension industry. This pulmonary arterial hypertension market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Technological advancements are key trends gaining popularity in the pulmonary arterial hypertension market. The companies operating in the pulmonary arterial hypertension drug sector are focusing on developing new medicines to improve and cure these diseases. For instance, in April 2021, United Therapeutics Corporation, a US-based biotechnology company, launched Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease. Tyvaso is an inhalation solution that helps patients enhance their exercise abilities, reduce breathing difficulties, have a low tolerance for exertion, and have a higher mortality rate.
In September 2021, Merck Group, a German-based multinational science and technology company that specialises in healthcare and life sciences solutions, acquired Acceleron Pharma for $11 billion. Through this acquisition, Merck will obtain ownership of Acceleron's portfolio of rare illness therapies, including sotatercept, a Phase III pulmonary arterial hypertension (PAH) medication, and also puts the company at the forefront of rare disease-focused companies. Acceleron Pharma is a US-based company committed to the research, development, and commercialization of therapies for the treatment of critical and uncommon conditions such as pulmonary arterial hypertension.
North America was the largest region in the pulmonary arterial hypertension market in 2022. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the pulmonary arterial hypertension market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The increasing prevalence of pulmonary arterial hypertension (PAH) disease is contributing to the growth of the pulmonary arterial hypertension market. The increasing prevalence of PAH diseases and the related hospitalisation of patients for treatment is expected to boost the demand for relevant drugs during the forecast period. According to a study published by the National Organization for Rare Disorders, Inc., new cases of PAH are estimated to occur in one to two individuals per million each year in the USA, which equates to 500-1000 new cases each year, and Europe is expected to have similar incidence rates.
The pulmonary arterial hypertension market includes revenues earned by entities by idiopathic, heritable, and drug and toxin-induced. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Major players in the pulmonary arterial hypertension market are United Therapeutics Corporation, Bayer AG, Gilead Sciences Inc., Johnson & Johnson, GlaxoSmithKline, Pfizer Inc., Sandoz AG, Lupin Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Acceleron Pharma Inc., Eli Lilly and Company, Actelion Pharmaceuticals US Inc., Natco Pharma Ltd., Zydus Pharmaceutical USA, and Liquidia Technologies Inc.,
This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Pulmonary Arterial Hypertension Market
What is the estimated value of the Global Pulmonary Arterial Hypertension Market?
What is the growth rate of the Global Pulmonary Arterial Hypertension Market?
What is the forecasted size of the Global Pulmonary Arterial Hypertension Market?
Who are the key companies in the Global Pulmonary Arterial Hypertension Market?
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2023 |
| Forecast Period | 2023 - 2027 |
| Estimated Market Value ( USD | $ 7.63 billion |
| Forecasted Market Value ( USD | $ 10.47 billion |
| Compound Annual Growth Rate | 8.2% |
| Regions Covered | Global |
Table of Contents
1. Executive Summary2. Pulmonary Arterial Hypertension Market Characteristics
3. Pulmonary Arterial Hypertension Market Trends And Strategies
4. Pulmonary Arterial Hypertension Market - Macro Economic Scenario
4.1 COVID-19 Impact On Pulmonary Arterial Hypertension Market
4.2 Ukraine-Russia War Impact On Pulmonary Arterial Hypertension Market
4.3 Impact Of High Inflation On Pulmonary Arterial Hypertension Market
5. Pulmonary Arterial Hypertension Market Size And Growth
5.1. Global Pulmonary Arterial Hypertension Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Pulmonary Arterial Hypertension Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Pulmonary Arterial Hypertension Market Segmentation
6.1. Global Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Endothelin Receptor Antagonists (ERAs)
- PDE-5 Inhibitors
- Prostacyclin and Prostacyclin Analogs
- SGC Stimulators
- Oral
- Intravenous/ subcutaneous
- Inhalational
- Retail
- Online
7.1. Global Pulmonary Arterial Hypertension Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Pulmonary Arterial Hypertension Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
8. Asia-Pacific Pulmonary Arterial Hypertension Market
8.1. Asia-Pacific Pulmonary Arterial Hypertension Market Overview
- Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.3. Asia-Pacific Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
9. China Pulmonary Arterial Hypertension Market
9.1. China Pulmonary Arterial Hypertension Market Overview
9.2. China Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
9.3. China Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
10. India Pulmonary Arterial Hypertension Market
10.1. India Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
10.2. India Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
11. Japan Pulmonary Arterial Hypertension Market
11.1. Japan Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
11.2. Japan Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
12. Australia Pulmonary Arterial Hypertension Market
12.1. Australia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
12.2. Australia Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
13. Indonesia Pulmonary Arterial Hypertension Market
13.1. Indonesia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
13.2. Indonesia Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
14. South Korea Pulmonary Arterial Hypertension Market
14.1. South Korea Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
14.2. South Korea Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
15. Western Europe Pulmonary Arterial Hypertension Market
15.1. Western Europe Pulmonary Arterial Hypertension Market Overview
15.2. Western Europe Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
15.3. Western Europe Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
16. UK Pulmonary Arterial Hypertension Market
16.1. UK Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
16.2. UK Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
17. Germany Pulmonary Arterial Hypertension Market
17.1. Germany Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
17.2. Germany Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
18. France Pulmonary Arterial Hypertension Market
18.1. France Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
18.2. France Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
19. Eastern Europe Pulmonary Arterial Hypertension Market
19.1. Eastern Europe Pulmonary Arterial Hypertension Market Overview
19.2. Eastern Europe Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
19.3. Eastern Europe Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
20. Russia Pulmonary Arterial Hypertension Market
20.1. Russia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
20.2. Russia Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
21. North America Pulmonary Arterial Hypertension Market
21.1. North America Pulmonary Arterial Hypertension Market Overview
21.2. North America Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
21.3. North America Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
22. USA Pulmonary Arterial Hypertension Market
22.1. USA Pulmonary Arterial Hypertension Market Overview
22.2. USA Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
22.3. USA Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
23. South America Pulmonary Arterial Hypertension Market
23.1. South America Pulmonary Arterial Hypertension Market Overview
23.2. South America Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
23.3. South America Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
24. Brazil Pulmonary Arterial Hypertension Market
24.1. Brazil Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
24.2. Brazil Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
25. Middle East Pulmonary Arterial Hypertension Market
25.1. Middle East Pulmonary Arterial Hypertension Market Overview
25.2. Middle East Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
25.3. Middle East Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
26. Africa Pulmonary Arterial Hypertension Market
26.1. Africa Pulmonary Arterial Hypertension Market Overview
26.2. Africa Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
26.3. Africa Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
27. Pulmonary Arterial Hypertension Market Competitive Landscape And Company Profiles
27.1. Pulmonary Arterial Hypertension Market Competitive Landscape
27.2. Pulmonary Arterial Hypertension Market Company Profiles
27.2.1. United Therapeutics Corporation
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Bayer AG
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Gilead Sciences Inc.
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Johnson & Johnson
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. GlaxoSmithKline
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Key Mergers And Acquisitions In The Pulmonary Arterial Hypertension Market
29. Pulmonary Arterial Hypertension Market Future Outlook and Potential Analysis
30. Appendix
30.1. Abbreviations
30.2. Currencies
30.3. Historic And Forecast Inflation Rates
30.4. Research Inquiries
30.5. About the Publisher
30.6. Copyright And Disclaimer
Executive Summary
Pulmonary Arterial Hypertension Global Market Report 2023 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on pulmonary arterial hypertension market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:
Where is the largest and fastest growing market for pulmonary arterial hypertension? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pulmonary arterial hypertension market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
Scope
Markets Covered:
1) By Drug Class: Endothelin Receptor Antagonists (ERAs); PDE-5 Inhibitors; Prostacyclin and Prostacyclin Analogs; SGC Stimulators2) By Route of Administration: Oral; Intravenous/ subcutaneous; Inhalational
3) By Distribution channel: Retail; Online
Companies Mentioned: United Therapeutics Corporation; Bayer AG; Gilead Sciences Inc.,; Johnson & Johnson; GlaxoSmithKline
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
A selection of companies mentioned in this report includes:
- United Therapeutics Corporation
- Bayer AG
- Gilead Sciences Inc.
- Johnson & Johnson
- GlaxoSmithKline
- Pfizer Inc.
- Sandoz AG
- Lupin Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
- Acceleron Pharma Inc.
- Eli Lilly and Company
- Actelion Pharmaceuticals US Inc
- Natco Pharma Ltd
- Zydus Pharmaceutical USA
- Liquidia Technologies Inc.,
Methodology
LOADING...
